Europsko izvješće o drogama 2026.: trendovi i razvoj – izvorni podatci
Ovaj skup podataka sadržava sve tablice s izvornim podatcima za Europsko izvješće o drogama 2026.: trendovi i razvoj. Ove tablice s podatcima upotrebljavaju se za izradu vizualizacija podataka i ostalih tablica u izvješću. Poveznice na tablice s izvornim podatcima za izradu vizualizacija podataka za određene odjeljke mogu se pronaći i na dnu svake stranice te, u većini slučajeva, ispod svakog grafičkog prikaza.
Napomene:
- Skup podataka prikazanih na ovoj stranici tek je mali podskup podataka prikupljenih od naših partnerskih organizacija. Više informacija i statističkih podataka, kao i detaljne metodološke bilješke i napomene potražite u Statističkom biltenu za 2026., koji je objavljen uz ovo izvješće.
- Ako nije drugačije navedeno, svi su skupovi podataka u potpunosti kompatibilni s licencijom Creative Commons Attribution 4.0 International (CC BY 4.0). To znači da slobodno možete ponovno upotrijebiti naše informacije i statističke podatke u svojem radu i istraživanju pod uvjetom da nas navedete kao izvor.
- Sve su datoteke u formatu CSV (vrijednosti odvojene zarezom), koji može otvoriti većina softvera za proračunske tablice ili softvera za statistiku.
Metodološke napomene
Podatci o prevalenciji konzumacije droga
- Ovdje predstavljeni podatci o prevalanciji temelje se na istraživanjima opće populacije koja su EUDA-i dostavile nacionalne središnjice informacijske mreže Reitox. Najnovije podatke i detaljne metodološke informacije potražite u Statističkom biltenu za 2026.: prevalencija konzumacije droga.
- Grafički prikazi s najnovijim podatcima na razini države temelje se na istraživanjima provedenima u razdoblju od 2015. do 2024.
- Pojam „amfetamini” odnosi se na amfetamin i metamfetamin. Ovdje predstavljeni podatci o prevalanciji temelje se na istraživanjima opće populacije koja su EUDA-i dostavile nacionalne središnjice.
- Procjene prevalencije za opću populaciju za kanabis: dobne su skupine za Njemačku, Grčku, Francusku, Italiju i Mađarsku 18 – 64 i 18 – 34 godine, za Dansku, Estoniju, Švedsku i Norvešku 16 – 64 i 16 – 34 godine, a za Maltu 18 – 65 i 18 – 34 godine.
- Procjene prevalencije za kokain: dobne su skupine za Njemačku, Grčku, Francusku, Italiju i Mađarsku 18 – 64 i 18 – 34 godine, za Dansku, Estoniju i Norvešku 16 – 64 i 16 – 34 godine, za Maltu 18 – 65 i 18 – 34 godine, a za Švedsku 17 – 34 godine.
- Procjene prevalencije za opću populaciju za amfetamine: dobne su skupine za Njemačku, Grčku, Francusku, Italiju i Mađarsku 18 – 64 i 18 – 34 godine, za Dansku, Estoniju i Norvešku 16 – 64 i 16 – 34 godine, za Maltu 18 – 34 godine, a za Švedsku 17 – 34 godine.
- Procjene prevalencije za opću populaciju za MDMA/ecstasy: dobne su skupine za Njemačku, Grčku, Francusku, Italiju i Mađarsku 18 – 64 i 18 – 34 godine, za Dansku, Estoniju i Norvešku 16 – 64 i 16 – 34 godine, za Maltu 18 – 65 i 18 – 34 godine, a za Švedsku 17 – 34 godine.
Podatci o potražnji za tretmanom
- Osim trendova, podatci se odnose na sve konzumente uključene u tretman, a kojima je ta tvar primarna droga – za 2024. ili posljednju godinu za koju su dostupni podatci.
- Trendovi u pogledu konzumenata koji su prvi put uključeni u tretman temelje se na podatcima za 26 država. Analizom trendova obuhvaćene su samo države s podatcima za najmanje šest od sedam godina. Vrijednosti koje nedostaju interpolirane su iz najbližih godina. S obzirom na poremećaje u pružanju usluga zbog pandemije bolesti COVID-19, podatke za 2020., 2021. i 2022. treba tumačiti s oprezom. Podatci koji nedostaju izvedeni su iz vrijednosti za prethodnu godinu za Španjolsku i Francusku (2024.) i Njemačku (2019.). U Njemačkoj na trendove utječe gotovo potpuni nestanak upućivanja iz kaznenopravnog sustava nakon promjene zakonodavstva u veljači 2024.
- Načini uporabe, heroin: „Drugi načini uporabe” uključuju jedenje/pijenje, ušmrkavanje i neodređene glavne načine uporabe. Trendovi se temelje na 19 država članica EU-a koje su dostavile podatke tijekom tog razdoblja, a uključene su samo one s podatcima za najmanje 9 od 11 godina. Vrijednosti koje nedostaju interpolirane su iz najbližih godina. S obzirom na poremećaje u pružanju usluga zbog pandemije bolesti COVID-19, podatke za 2020., 2021. i 2022. treba tumačiti s oprezom.
Podatci o opskrbi i tržištu
- Navedeni pokazatelji trendova odražavaju relativne promjene u zapljenama droga tijekom desetogodišnjeg razdoblja, ali ne upućuju na stvarne količine.
- Tablete MDMA-a preračunate su u ekvivalent mase uz pretpostavku da jedna tableta sadržava 0,25 grama MDMA-a.
- EU+2 odnosi se na države članice EU-a te Norvešku i Tursku.
- Cijena i potentnost: nacionalne srednje vrijednosti – minimum, maksimum i interkvartilni raspon. Države se razlikuju prema pokazateljima.
Podatci o otpadnim vodama
- Prosječne dnevne količine ciljne droge iskazane su u miligramima na 1000 stanovnika. U većini gradova uzorkovanje je provedeno tijekom jednog tjedna između ožujka i svibnja 2025.
- Uzimajući u obzir statističke pogreške, vrijednosti koje se razlikuju za manje od 10 % od prethodne vrijednosti smatraju se stabilnima u tablicama u kojima su prikazane promjene između 2024.i 2025.
- Izvor: Središnja europska skupina za analizu nezakonitih droga u kanalizaciji (SCORE).
- Za potpuni skup podataka i analizu vidjeti Analiza otpadnih voda i droga – europsko istraživanje koje obuhvaća više gradova.
Podatci mreže Euro-DEN Plus
- Za podatke o promjenama u odnosu na prethodnu godinu vrijednosti koje se razlikuju za manje od 10 % od prethodne vrijednosti smatraju se stabilnima. Zastupljeni su samo centri koji prijavljuju najmanje 20 slučajeva za svaku godinu.
- U Bratislavi, Bukureštu, Gdanjsku i Rigi 2024. bilo je 10 ili manje slučajeva povezanih s kokainom, što je ograničilo usporedivost među godinama. Najnovije podatke i detaljne metodološke informacije potražite u: pregledniku podataka mreže Euro-DEN.
Podatci za testiranje sastava droga
- Transeuropska informacijska mreža o drogama (TEDI). Podatci iz 11 europskih službi za testiranje sastava droga u sedam država članica EU-a, 2024. i 2025.
Podatci o smrtnim slučajevima uzrokovanima konzumacijom droga
- Udio smrtnih slučajeva u kojima su spomenuti opioidi: podatci iz posebnih registra smrtnosti. Obuhvaćene su države s najmanje 70 prijavljenih slučajeva. Države su poredane silaznim redoslijedom prema udjelu slučajeva koji uključuju heroin. U nekim državama nedostaju pojedinosti o tome koji su točno opioidi uključeni.
- Podatci o trendovima: usporedivi podatci za Njemačku nisu dostupni prije 2021. godine. Za vizualizaciju trenda ranije su godine popunjene prvom raspoloživom vrijednošću. Međutim, prema nacionalnoj definiciji koja je tada bila u upotrebi, broj smrtnih slučajeva uzrokovanih konzumacijom droga u Njemačkoj povećavao se do 2020. Za neke države nisu dostupni podatci za 2023. ili 2024. U tim slučajevima upotrijebljeni su najnoviji dostupni podatci umjesto vrijednosti koje nedostaju (2022. za Belgiju, Irsku, Grčku, 2023. za Španjolsku, Francusku, Poljsku, Portugal).
Podatci o smanjenju štete
- Podjela igala i šprica te pokrivenost terapijom opioidnim agonistima u odnosu na ciljeve Svjetske zdravstvene organizacije iz 2025.: pokrivenost se temelji na najnovijim nacionalnim procjenama intravenske konzumacije droga i visokorizične konzumacije opioida, koje su usklađene s podatcima o aktivnosti smanjenja štetnih posljedica (u roku od najviše dvije godine). Procjena pokrivenosti terapijom opioidnim agonistima za Belgiju izvedena je iz istraživanja provedenog 2019. na podnacionalnoj razini.
- Nalokson za kućnu konzumaciju: Podatci se odnose na države članice EU-a, Norvešku i Tursku u 2024. U Grčkoj je 2023. donesen zakon o naloksonu za kućnu konzumaciju, a 2025. ministarstvo je donijelo odluku kojom se omogućuje provedba programa.
- Table EDR26-GPS-1. Prevalence of drug use in Europe, based on most recent general population surveys (2024 or most recent year)
- Table EDR26-GPS-2. Prevalence of drug use in Europe, trends
- Table EDR26-WW-1. Mean weekly measurements by targeted substance from wastewater analysis in selected European cities in 2025
- Table EDR26-TDI-1. Treatment demand indicator (TDI) source data, client characteristics, 2024 or most recent year. Percentages except where otherwise stated
- Table EDR26-Sup-1. Number of reported drug seizures, breakdown by drug, 2024
- Table EDR26-Sup-2. Drug seizures in the European Union — number of drug seizures, indexed trends (2014 = 100)
- Table EDR26-Sup-3. Drug seizures in the European Union — quantity of drugs seized, indexed trends (2014 = 100)
- Table EDR26-Sup-4. Drug seizures in the European Union — number of seizures in 2024
- Table EDR26-Sup-5. Drug seizures in the European Union — quantity seized in 2024 (tonnes)
- Table EDR26-Sup-6. Drug law offences — possession/use offences, indexed trends (2014 = 100)
- Table EDR26-Sup-7. Drug law offences — supply offences, indexed trends (2014 = 100)
- Table EDR26-Sup-8. Drug law offences — number of offences, supply and use/possession, 2024
- Tablica EDR26-Sup-9. Quantity of precursors (EU) and key non-scheduled chemicals seized in the European Union (2012-2024)
- Table EDR26-Sup-10. Quantities of precursors and key non-scheduled chemicals seized in the European Union in 2024 (kilograms), by their association with drug production
- Table EDR26-Sup-11. Quantities of key precursor chemicals seized in the European Union in 2024 (litres), by association with drug production
- Table EDR26-Sup-12. Summary of seizures of EU scheduled precursors and non-scheduled chemicals used for selected drugs produced in the European Union, 2024
- Table EDR26-Cannabis-3. Trends in first-time entrants, cannabis, selected countries
- Table EDR26-Cannabis-4. Cannabis markets seizures source data, 2024 or most recent year
- Table EDR26-Cannabis-5. Trends in the number of cannabis seizures and quantity of illicit drugs seized (x 1000)
- Table EDR26-Cannabis-6. Trends in the quantities of cannabis seizures and quantity of illicit drugs seized (tonnes)
- Table EDR26-Cannabis-7. Price, potency data for cannabis, 2024 or most recent year
- Table EDR26-Cannabis-8. Price and purity/potency indexed trends
- Table EDR26-Cocaine-3. Trends in first-time entrants, cocaine, selected countries
- Table EDR26-Cocaine-4. Cocaine markets seizures source data
- Table EDR26-Cocaine-5. Trends in the number of cocaine seizures and quantity of illicit drugs seized (x 1000)
- Table EDR26-Cocaine-6. Trends in the quantities of cocaine seizures and quantity of illicit drugs seized (tonnes)
- Table EDR26-Cocaine-7. Price, potency data for cocaine, 2024 or most recent year
- Table EDR26-Cocaine-10. Price and purity/potency indexed trends, cocaine
- Table EDR26-Cocaine-9. Trends in the numbers of cocaine-related presentations in Euro-DEN Plus sentinel hospitals 2023 to 2024
- Table EDR26-Cocaine-11. Polysubstance toxicity in drug-related deaths cases with cocaine involved
- Table EDR26-Stimulants-1. Amphetamine and methamphetamine entrants as a share of all first-time treatment entrants
- Table EDR26-Stimulants-2. Trends in all entrants for synthetic cathinone users
- Table EDR26- Stimulants-3. Synthetic stimulants seizures source data, 2024 or most recent year
- Table EDR26-Stimulants-4. Synthetic stimulants market price and purity data, 2024 or most recent year
- Table EDR26-Stimulants-7. Trends in the quantities of synthetic stimulants seized, tonnes 2014-2024
- Table EDR26-Stimulants-6. Trends in the number of synthetic stimulants seizures 2014-2024
- Table EDR26-Stimulants-5. Synthetic stimulants retail market price and purity data indexed trends (2014=100)
- Table EDR26-MDMA-2. MDMA markets seizures source data, 2024 or most recent year
- Table EDR26-MDMA-5. Trends in the number of MDMA seizures
- Table EDR26-MDMA-4. Trends in the quantity of MDMA seized: tablets
- Table EDR26-MDMA-5. Trends in the quantity of MDMA seized: powder (tonnes)
- Table EDR26-MDMA-6. MDMA price and purity or content data, 2024 or most recent year
- Table EDR26-MDMA-7. Price and MDMA content indexed trends
- Table EDR26-MDMA-8. MDMA purity or content of samples submitted to drug checking services (percent), 2024
- Table EDR26-MDMA-9. Psychoactive adulterants detected in samples sold as MDMA to users and tested in 12 European drug checking services, 2024
- Table EDR26-Heroin-1. Age distribution of all clients entering treatment with heroin as their primary drug, 2010 and 2024 (%)
- Table EDR26-Heroin-2. Age distribution of never previously treated clients entering treatment with heroin as their primary drug, 2010 and 2024 (%)
- Table EDR26-Heroin-3. Trends in first-time heroin treatment entrants
- Table EDR26-Heroin-4. Trends in the main route of administration of clients entering treatment with heroin as primary drug, by treatment status (%)
- Table EDR26-Heroin-5. Heroin markets seizures source data
- Table EDR26-Heroin-6. Trends in the number of heroin seizures (x 1000)
- Table EDR26-Heroin-7. Trends in the quantities of heroin seizures (tonnes)
- Table EDR26-Heroin-8. Price, potency data for heroin
- Table EDR26-Heroin-9. Price and purity/potency indexed trends, heroin
- Table EDR26-Heroin-10a. Proportion of the acute drug toxicity presentations with heroin involved in 2023
- Table EDR26-Heroin-10b.Trends in the proportion of the acute drug toxicity presentations with heroin involved in selected hospitals in Europe
- Table EDR26-Heroin-12. Other opioids: number of seizures and quantities seized, 2023
- Table EDR26-NPS-1. Number of new psychoactive substances reported for the first time to the EU Early Warning System, by category, 2005–2024
- Table EDR26-NPS-2. Number of new psychoactive substances reported each year following their first detection in the European Union, by category, 2005–2024
- Table EDR26-NPS-3a. Seizures of new psychoactive substances in the European Union: total number and total quantity of material seized, 2005–2024
- Table EDR26-NPS-3b. Seizures of new psychoactive substances in the European Union: total number of material seized, 2005–2024
- Table EDR26-NPS-4. Number of opioids reported for the first time to the EU Early Warning System, 2009–2024
- Table EDR26-NPS-5. Seizures of new psychoactive substances in the European Union: quantity seized, by substance, 2024
- Table EDR26-NPS-6. Notifications of new psychoactive substances under the terms of Regulation (EC) no 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) – 2024
- Table EDR24-Ketamine-1a. Seizures of ketamine powder in the European Union: total number, 2006–2024
- Table EDR26-Ketamine-1b. Seizures of ketamine powder in the European Union: total quantity, 2006-2024
- Table EDR26-Ketamine-2. Ketamine residues detected in wastewater in selected European cities: 2024
- Table EDR26-BZD-1. Number of formal notifications of benzodiazepines reported to the EU Early Warning System, 2011-25
- Table EDR26-Other-8a. Number of seizures and quantity seized of other drugs, European Union, 2024
- Table EDR26-Other-8b. Number of seizures and quantity seized of other drugs, European Union, Norway and Türkiye, 2024 or most recent year
- Table EDR26-Other-9. Proportion of all acute drug toxicity presentations related to GHB/GBL (percent), 2024
- Table EDR26-INJ-1a. Estimated number and prevalence of people who inject drugs, by country (latest available data for each country)
- Table EDR26-INJ-1b. Estimated prevalence (per 1000 people) of people who inject drugs, (latest available data for each country)
- Table EDR26-INJ-2. Trends in injecting among first-time treatment entrants with heroin, cocaine, amphetamine or methamphetamine as primary drug: percentage reporting injecting as main route of administration
- Table EDR26-INJ-3a. European Syringe Collection and Analysis Project Enterprise (ESCAPE) selected data for 2024
- Table EDR26-INJ-3b. ESCAPE project site location data
- Table EDR26-DRID-1. New HIV notifications linked to injecting drug use in the European Union, 2009 to 2024
- Table EDR26-DRID-2. Most-recent HIV outbreaks in Europe among people who inject drugs and the associated injected substance, 2014 to 2024
- Table EDR26-DRID-3. Number of sterile syringes distributed per person who inject drugs per year, 2024 or latest data
- Table EDR26-DRID-5a. New HIV cases attributable to injecting drug use, 2024 or most recent year
- Table EDR26-DRID-5b. New AIDS cases attributable to injecting drug use, 2024 or most recent year
- Table EDR26-DRID-5c. Trends in drug-related HIV: EU and selected countries (cases per million population)
- Table EDR26-DRID-5d. Countries with national data on HCV and HBV, 2024
- Table EDR26-DRID-6. Prevalence of active HCV infection among people who inject drugs, by country, 2024 or latest available data
- Table EDR26-DRID-7. Trends in HCV-RNA prevalence (%) among people who inject drugs: results from seroprevalence studies, 2013-2024
- Table EDR26-DRD-1. Characteristics of drug-induced deaths: numbers, 2024 or most recent year
- Table EDR26-DRD-1. Characteristics of drug-induced deaths: numbers, 2024 or most recent year
- Table EDR26-DRD-1a. Characteristics of drug-induced deaths: gender (percent), 2024 or most recent year
- Table EDR26-DRD-1b. Characteristics of drug-induced deaths: age (by gender), 2024 or most recent year
- Table EDR26-DRD-2. Age distribution of drug-induced deaths reported in the European Union, Norway and Türkiye in 2024 or the most recent year
- Table EDR26-DRD-3. Proportion of males among drug-induced deaths in the European Union, Norway and Türkiye in 2024, or most recent year (percent)
- Table EDR24-DRD-4. Drug-induced deaths in the European Union: age at death, 2024 or most recent available data (percent)
- Table EDR26-DRD-7. Proportion of drug-induced deaths cases with opioids mentioned, 2024 or most recent available data
- EDR26-DRD-5 Number of drug-induced deaths reported in the European Union in 2014 and 2024, or the most recent year, by age band
- Table EDR24-DRD-6. Trends in drug-induced deaths in the European Union, Norway and Türkiye
- Table EDR26-DRD-10. Opioids mentioned in drug-induced deaths, by substance
- Table EDR26-DRD-11. Number and rates per million population of drug-induced deaths reported in the European Union in 2014 and 2024, or the most recent year, by sex and age band
- Table EDR26-OAT-1. Coverage of opioid agonist treatment in 2024 or the most recent year and 2013/14 (Percent)
- Table EDR26-OAT-2. Clients in opioid agonist treatment
- Table EDR26-OAT-3 Number of European countries implementing opioid agonist treatment, up to 2025
- Table EDR26-HR-1. Number of European countries implementing harm reduction interventions, up to 2025
- Table EDR26-HR-2. Availability of take-home naloxone in Europe
- Table EDR26-HR-3. Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2020 targets, 2023 or latest available estimate
- Table EDR26-HR-4. Location and number of drug consumption facilities throughout Europe 2025
- Table EDR26-HR-5. Availability of drug-related and other health and social care interventions targeting people who use drugs and are in prison, EU+2, 2024
- Table EDR26-Annex-table-1a. High-risk opioid use estimates for population aged 15–64 years, 2024 or most recent year
- Table EDR26-Annex-table-1b. Entrants into treatment during the year: opioids clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-1c. Entrants into treatment during the year: proportion of opioids clients with injection as main route of administration, 2024 or most recent year
- Table EDR26-Annex-table-1d. Number of clients in opioid agonist treatment, 2024 or most recent year
- Table EDR26-Annex-table-2a. Cocaine prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-2b. Entrants into treatment during the year - cocaine clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-2c. Entrants into treatment during the year: proportion of cocaine clients with injection as main route of administration, 2024 or most recent year
- Table EDR26-Annex-table-3a. Amphetamines prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-3b. Entrants into treatment during the year - amphetamines clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-3c. Entrants into treatment during the year: proportion of amphetamines clients with injection as main route of administration, 2024 or most recent year
- Table EDR26-Annex-table-4a. MDMA prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-4b. Entrants into treatment during the year - MDMA clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-5a. Cannabis prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-5b. Entrants into treatment during the year - cannabis clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-6. Drug-induced deaths, HIV diagnoses, injecting drug use estimates, syringes distributed through specialised programmes, 2024 or most recent year
- Table EDR26-Annex-table-7. Seizures data, 2024 or most recent year
- Table EDR26-At-a-glance-1. Drug use in the EU in 2024, at a glance (amphetamines, cannabis, cocaine, MDMA)
- Table EDR26-At-a-glance-2. Heroin and other opioids in the EU in 2024, at a glance